EBR Systems (ASX:EBR) is a medical device company that develops and commercialises the WiSE CRT™ System, the world's first and only leadless cardiac pacing device for heart failure. Leadless CRT is a minimally invasive therapy that can be implanted without the need for wires or leads, and it offers a number of advantages over traditional CRT devices, including reduced risk of infection and lead-related complications. EBR Systems' operations are focused on the commercialization of the WiSE CRT System in the United States, the world's largest market for CRT devices. The company is currently conducting a pivotal clinical trial to support FDA approval of the WiSE CRT System, and it expects to launch the device commercially in the United States in 2024.